Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval | Antibodies

Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval

Related Keywords

Sweden ,Japan ,Stockholm , ,National Institutes Of Health ,National Institute On ,Ministry Of Health ,Drug Administration ,Devices Agency ,Alzheimer Clinical Trial Consortium ,Swedeni March ,Nasdaq Stockholm ,Medical Devices Agency ,Biologics License Application ,Accelerated Approval ,Clinical Trial Consortium ,National Institute ,National Institutes ,Breakthrough Therapy ,Commercialization Agreement ,Biologics ,Antibodies ,Therapeutic Antibodies ,Recombinant ,Antibody Drug Conjugates ,Dc ,Immunoconjugates ,Biosimilar Antibodies ,Biosuperior Antibodies ,Antibody Fragments ,Scfv ,Lab ,Nanobodies ,Domain Antibodies ,Manufacturing ,